How Biotechs Can Navigate Market Uncertainty In 2025
By Tyler Menichiello, contributing editor
The biotech funding climate has been turbulent in recent years, and political influences may either quell or continue this turbulence. In this segment from “Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond,” CEO, co-founder, and president of Ossium Health, Kevin Caldwell; CSO of FibroBiologics, Hamid Khoja, Ph.D.; and president and acting CEO of Triumvira Immunologics, Rob Williamson, weigh in on how to prepare for what may be a challenging financial climate in 2025. While a lot of factors are outside of individual control, the panelists agree that operating lean can help companies weather the storm of market uncertainty.
This website uses cookies to ensure you get the best experience on our website. Learn more